产品展示
BXC-SIM0010体内SIM人类PD-1抗体(帕博利珠单抗生物类似药)
点击次数:0发布时间:2023/3/17 15:29:13
更新日期:2023/3/17 15:29:13
所 在 地:中国大陆
产品型号:
优质供应
详细内容
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Pembrolizumab making it ideal for research use. This Pembrolizumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being used as cancer treatments. Pembrolizumab binds to PD-1 on activated immune cells to selectively block the interaction of PD-1 with its ligands.
BXC-SIM0010体内SIM人类PD-1抗体(帕博利珠单抗生物类似药):
这种非治疗性生物仿制药抗体使用与治疗性抗体Pembrolizumab相同的可变区域,使其成为研究用途的理想选择。这种Pembrolizumab生物仿制药与人PD-1(程序性死亡-1)反应,也称为CD279。PD-1是由Pdcd50基因编码的55-1 kDa细胞表面受体,属于Ig超家族的CD28家族。PD-1在CD4和CD8胸腺细胞以及活化的T和B淋巴细胞和骨髓细胞上短暂表达。PD-1在成功消除抗原后表达下降。
BioXCell艾美捷体内SIM人类PD-1抗体(帕博利珠单抗生物类似药)规格:
# BXC-SIM0010
Isotype Human IgG4
Recommended Isotype Control(s) RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen Human PD-1
Reported Applications Blocking of PD-1/PD-L signaling
Functional assays
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <1EU/mg (<0.001EU/μg)
Determined by LAL gel clotting assay
Aggregation <5%
Determined by DLS
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 μM filtered
Production Purified from cell culture supernatant
Purification Protein A
RRID AB_2894731
Molecular Weight 150 kDa
Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
同种型 人免疫球蛋白G4
推荐的同种型对照 RecombiMAb人IgG4(S228P)同种型对照,抗母蛋溶菌酶
推荐的稀释缓冲液 体内纯 pH 7.0 稀释缓冲液
免疫原 人类PD-1
报告的应用程序 阻断PD-1/PD-L信号传导
功能检测
配方 PBS,pH 7.0
不含稳定剂或防腐剂
内毒素 <1EU/mg (<0.001EU/μg)
通过LAL凝胶凝血测定法测定
集合体 <5%
由 DLS 确定
纯度 >95%
由 SDS-PAGE 决定
无 菌 0.2 μM 过滤
生产 从细胞培养上清液中纯化
纯化 蛋白A
里德 AB_2894731
分子量 150 千达
鼠病原体检测 外切粒菌/鼠痘病毒: 阴性 汉坦病毒: 阴性 K 病毒: 阴性乳酸脱氢酶升高病毒: 阴性 淋巴细胞性脉络丛脑膜炎病毒: 阴性小鼠腺病毒: 阴性小鼠巨细胞病毒: 阴性小鼠肝炎病毒: 阴性小鼠分钟病毒: 阴性小鼠诺如病毒: 阴性小鼠细小病毒: 阴性
小鼠轮状病毒:肺支原体阴性:阴性 小鼠肺炎病毒:阴性 多瘤病毒:阴性呼肠孤病毒筛查:阴性 仙台病毒:阴性 泰勒鼠脑脊髓炎:阴性
存储 抗体溶液应以4°C的储备浓度储存。 不要冻结。